Biomarkers: Impact on Treatment Choices and Future Expectations
The key opinion leaders share their strategies for selecting systemic therapy, comparing immunotherapy combination (IO/IO) versus immunotherapy plus tyrosine kinase inhibitor (IO/TKI) approaches, for previously untreated patients with advanced renal cell carcinoma.
- Dr McKay and Campbell: Please discuss your treatment approach to systemic therapy (IO/IO vs. IO/TKI) for treatment-naïve patients with advanced RCC.
- How do the most recent data updates for CM-214, CLEAR, KN-426, and CM-9ER impact your treatment decisions?
- Please discuss the importance of biomarkers in determining appropriate treatment options.
- CLEAR – biomarker analysis (Choueiri, TK, et al. 2024 ASCO Annual Meeting. Abstract 4504).
- CheckMate -214 – biomarker analysis (Matar, S, et al 2024 ASCO Annual Meeting. Abstract 4536).
- Keynote-426 – biomarker analysis (Rini BI, et al. 2024 ASCO Annual Meeting. Abstract 4505).
- Do you have a “go-to” treatment?
- How do you factor OS, PFS, and DOR into your decision-making?
- Does it differ for those with intermediate/poor risk vs. favorable risk disease?
- If so, what patient-specific variables would cause you to re-evaluate your treatment choice(s)?
- Age? Tumor burden? Kidney function? Performance status? Chronic comorbidities?
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
